Antiproteinuric effect of recombinant human erythropoietin (rHuEPO) in predialysis chronic kidney disease (CKD) patients: multicenter observational study

Antiproteinuric effect of recombinant human erythropoietin (rHuEPO) in predialysis chronic kidney disease (CKD) patients: multicenter observational study - Antiproteinuric effect of rHuEPO in predialysis CKD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001634

Enrollment

Registered

2009-01-14

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Predialysis CKD patients treated with recombinant human erythropoietin (rHuEPO)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients with chronic kidney disease (CKD) who had been examined urinary protein:urinary creatinine ratio for at leaset 3 months before- and after- starting rHuEPO.

Exclusion criteria

Exclusion criteria: Patients with cancer, liver cirrhosis, maintenance dialysis and pregnancy were excluded. Patients who were started or changed with antihypertensives or diuretics or who required admission within 6 months before- and after- rHuEPO initiation.

Design outcomes

Primary

Measure	Time frame
Reduction in proteinuria	—

Secondary

Measure	Time frame
Correlation between reduction in proteinuria and increase in Hb.	—

Countries

Japan

Contacts

Public ContactYoshiyuki Furumatsu

Osaka University Graduate School of Medicine Nephrology

furumatsu@yahoo.co.jp06-6879-3857

Outcome results